Shelved 4-1BB Antibodies Make Comeback.
New trials are reexamining 4-1BB antibodies for a variety of cancers. Development of the drugs had stalled due to concerns about toxicity, but recent studies in animals, as well as early-phase trials, suggest that new formulations of the drugs may be less toxic-and potentially more potent-when combined with other therapies.